[ad_1]
The results of DECLARE, the largest clinical study to evaluate a new class of type 2 antidiabetic drugs called "SGLT-2 inhibitors" and presented at the American Heart Association conference in 2018, showed that the dapagliflozin, developed by AstraZeneca "AstraZeneca reduces by 17% the risk of hospitalization because of heart failure or death from cardiovascular disease, allows to obtain positive results in kidney failure and has a good degree of security.
"Doctors have always focused on reducing blood sugar in people with diabetes, but the fact is that type 2 diabetics are likely to suffer complications leading to other diseases, including diabetes. Heart failure, which means that our way of reducing blood sugar levels is very important, "said Dr. Paula Attallah, president of the Lebanese Association of Endocrinology, Diabetes and Cancer. obesity. "We should choose drugs that improve outcomes for patients' health."
About DECLARE
DECLARE-TIMI 58 (Effect of Dapagliphlozine on Cardiovascular Disease) is a large, single multinational study designed to evaluate the efficacy of dapagliphlozine in the treatment of cardiovascular disease and its safety.
The study included approximately 17,160 patients with type 2 diabetes in 33 countries with multiple risk factors (60%) such as blood lipids, high blood pressure or smoking, or confirmed cardiovascular disease (40%) followed. Over the next 4.2 years, it is the largest in its category to date, the longest in terms of patient follow-up and the largest in terms of representation of this group of patients.
Professor Fadi Haddad, former president of the Lebanese Association of Internal Medicine, emphasized that "the patients studied in DECLARE are the ones we will encounter in our daily practice".
This study is unique in that it is the first drug in its class that evaluates hospitalization for heart failure or death related to cardiovascular disease as an additional key criterion of the study.
Between the heart and diabetes
Heart failure is more common than heart attacks and strokes in patients with type 2 diabetes and cardiovascular disease. Heart failure negatively affects the quality of life of patients and leads to exhaustion, shortness of breath and frequent hospitalization.
Professor Antoine Sarkis, president of the Lebanese Association of Cardiologists, said: "Rates of heart failure can reach 50% just five years after diagnosis." "Reducing the hospitalization rate for heart failure by 27% in a large group of patients, only 10% of whom have heart failure at baseline, is a very important outcome," he said. Glucose in the blood, to better treat the complications of serious cardiovascular diseases often neglected. "
About diabetes, heart and kidney disease
There is a strong link between diabetes and cardiovascular disease, which is the leading cause of morbidity and mortality in people with diabetes. Diabetes can also lead to heart failure, a heart condition that prevents the heart from pumping enough blood to meet the needs of the body.
Sixty-eight percent of patients with type 2 diabetes were exposed to left ventricular weakness five years after initial diagnosis.
In fact, the heart and kidneys are closely linked and any effect on one of them increases the damage of the other. Chronic nephropathy is a complication of early and recurrent type 2 diabetes. Studies have shown that up to 40% of type 2 diabetic patients would later suffer from nephropathy.
In this regard, Dr. Heba Hajar Baroudi, Chief Medical Officer for Cardiovascular, Renal and Metabolic Diseases at Astra Zeneca in the Near East, noted that AstraZeneca is currently leading a research group on the possible effects of dapagliphlozin, the development of heart disease or chronic kidney disease in patients with or without type 2 diabetes. "
Learn more about Dapagipluzin
Dapagliphlozine is a biochemical inhibitor of the sodium and glucose transporter (SGLT2) that acts independently of insulin to help remove excess glucose from the body in a unique way. Dapagliphlozine is an approved drug for the treatment of type 2 diabetes.
The treatment of kidneys reacts via an inhibition of SGLT2, which eliminates excess glucose (about 2,100 grams of glucose per month) and calories produced in the urine (about 8,400 kcal / month).
It should be noted that According to estimates, the number of diabetics in Lebanon reached 8% of adults aged 20 to 79 in 2017, which represents 585,400 people in this age group.
[ad_2]
Source link
